「gui」の検索結果

Analyzes base-editing screens for variant function. Covers library design (Hanna 2021 ClinVar-scale CBE screen benchmarked on BRCA1/2, Cuella-Martin 2021 DDR saturation), CBE vs ABE chemistry choice (BE3/BE4 vs ABE7.10/ABE8.20/ABE8e), editing-window math (positions 4-8 from PAM-distal end; 4-7 for ABE7.10), bystander-edit quantification and the variant-call ambiguity it creates, sgRNA-efficiency filtering before hit calling, indel byproduct interpretation, the substitution-vs-indel diagnostic, variant annotation against ClinVar / COSMIC, and the Broad be-validation-pipeline. Use when designing a BE variant screen, choosing CBE vs ABE for a specific edit, interpreting bystander-confounded hits, distinguishing functional signal from indel artifact, integrating CRISPResso2 output with screen scoring, or deciding BE vs PE for SNV installation.

日本語の概要は準備中です。原文の説明を表示しています。

Quantifies CRISPR editing outcomes with CRISPResso2 (Clement 2019 Nat Biotechnol) across Cas9-nuclease (indels, HDR), CBE and ABE base editors (target conversion + bystander), and prime editor (pegRNA-templated) modes. Covers single-amplicon (CRISPResso), multi-sample batch (CRISPRessoBatch), pooled-amplicon (CRISPRessoPooled), WGS off-target (CRISPRessoWGS), and sample-comparison (CRISPRessoCompare) workflows; quantification-window math that controls what is called edited; substitution-vs-indel diagnostic to distinguish BE from Cas9 contamination; MMEJ deletion pattern interpretation; allele-frequency tables; and failure modes from amplicon misalignment or contamination. Use when quantifying editing from amplicon sequencing, choosing CRISPResso mode by design, distinguishing intended edits from bystanders and indel byproducts, debugging low-alignment runs, or generating publication-grade editing reports.

日本語の概要は準備中です。原文の説明を表示しています。

Queries PharmGKB / CPIC / DPWG for drug-gene interactions; calls CYP2D6/CYP2C9/CYP2C19/DPYD/TPMT/NUDT15/UGT1A1/SLCO1B1 star alleles and phenotype with PharmCAT, Cyrius (CYP2D6 structural variants), Aldy, Stargazer; applies Caudle 2020 activity-score translation. Use when implementing pharmacogenomic-guided prescribing, applying CPIC vs DPWG guidance, screening HLA risk alleles for ICI / antiepileptics / abacavir, or interpreting compound TPMT+NUDT15 thiopurine risk.

日本語の概要は準備中です。原文の説明を表示しています。

Guidance for choosing the right protein binder design tool. Use this skill when: (1) Deciding between BoltzGen, BindCraft, or RFdiffusion, (2) Planning a binder design campaign, (3) Understanding trade-offs between different approaches, (4) Selecting tools for specific target types. For specific tool parameters, use the individual tool skills (boltzgen, bindcraft, rfdiffusion, etc.).

日本語の概要は準備中です。原文の説明を表示しています。

Expert guide for Backend.AI distributed computing platform. Automatically activates when users ask about: - Backend.AI architecture, components (Manager, Agent, Storage Proxy, Webserver, App Proxy) - Features (session scheduling, Sokovan orchestrator, multi-tenancy, resource allocation) - APIs (REST, GraphQL), authentication, RBAC authorization - Container runtime (kernels, jail sandbox, hook library, virtual folders) - Accelerator support (CUDA, ROCm, TPU, NPU, Graphcore IPU) - Client SDKs (Python, Java, JavaScript, PHP) - Setup, requirements (Python 3.13+, Docker, PostgreSQL, Redis, etcd) - How WebUI connects to/interacts with Backend.AI backend - Plugin interfaces, development setup, infrastructure Use when user mentions "Backend.AI", "backend.ai", "Sokovan", component names, or asks about the backend platform this WebUI connects to. allowed-tools: WebFetch, Read

日本語の概要は準備中です。原文の説明を表示しています。

Comprehensive backend development guide for Langfuse's Next.js 14/tRPC/Express/TypeScript monorepo. Use when creating tRPC routers, public API endpoints, BullMQ queue processors, services, or working with tRPC procedures, Next.js API routes, Prisma database access, ClickHouse analytics queries, Redis queues, OpenTelemetry instrumentation, Zod v4 validation, env.mjs configuration, tenant isolation patterns, or async patterns. Covers layered architecture (tRPC procedures → services, queue processors → services), dual database system (PostgreSQL + ClickHouse), projectId filtering for multi-tenant isolation, traceException error handling, observability patterns, and testing strategies (Jest for web, vitest for worker).

日本語の概要は準備中です。原文の説明を表示しています。

Write articles, guides, blog posts, tutorials, newsletter issues, and other long-form content in a distinctive voice derived from supplied examples or brand guidance. Use when the user wants polished written content longer than a paragraph, especially when voice consistency, structure, and credibility matter.

日本語の概要は準備中です。原文の説明を表示しています。

Frontend development guidelines for React/TypeScript applications. Modern patterns including Suspense, lazy loading, useSuspenseQuery, file organization with features directory, MUI v7 styling, TanStack Router, performance optimization, and TypeScript best practices. Use when creating components, pages, features, fetching data, styling, routing, or working with frontend code.

日本語の概要は準備中です。原文の説明を表示しています。

Pre-routing ambiguity analysis — scores request clarity and asks clarifying questions when needed (inspired by ouroboros)

日本語の概要は準備中です。原文の説明を表示しています。

Skill for adding or updating system design guides tailored for college students and beginners, using simple analogies and no simulations.

日本語の概要は準備中です。原文の説明を表示しています。

Skill for adding or updating educational algorithm guides, ensuring consistent patterns and simple explanations suitable for an 8-year-old.

日本語の概要は準備中です。原文の説明を表示しています。

Bridge Codex to web-based AI model products by packaging local task context, scrub-checking it, sending it through an approved browser surface to ChatGPT Pro, Claude, Grok, Gemini, or another web model, waiting for the answer, and returning the model response to the user or Codex. Also guide DevSpace-like MCP Connector Mode when the user wants ChatGPT Pro or another MCP-capable web host to access approved local workspaces without relying on Codex browser automation. Use when the user asks for GPT Pro, ChatGPT Pro, Claude web, Grok, Gemini web, web model bridge, external model consult, ask another model, second opinion, use a web AI model, browserless agent access to GPT Pro, MCP connector, DevSpace-like workflow, or send local repo context to a browser-based model for planning, review, debugging, architecture discussion, or implementation guidance.

日本語の概要は準備中です。原文の説明を表示しています。

Guides product-design decisions using the consuming repository's design-system, product, and repository context. Use when designing UI, choosing layout or navigation, handling states and forms, messaging, disclosure, onboarding, visualization, copy, delete, filter, or search interactions. Triggers on 'design guidance', 'how to design', 'UI pattern', 'product design', 'scenario pattern', 'confirmation dialog', 'delete flow', 'copy to clipboard', 'filter', and 'search'.

日本語の概要は準備中です。原文の説明を表示しています。

This skill provides criteria to distinguish unilateral from bilateral primary aldosteronism using adrenal venous sampling results, including lateralization index, contralateral ratio, and clinical factors. It is triggered after AVS when clinicians analyze results and ask 'Is this unilateral or bilateral PA?' or need to guide treatment decisions.

日本語の概要は準備中です。原文の説明を表示しています。

Helps distinguish unilateral from bilateral adrenal disease based on 18-oxocortisol levels, which are typically higher in aldosterone-producing adenoma than idiopathic adrenal hyperplasia. Use when evaluating 18-oxocortisol results during PA workup to guide subtype classification after a positive ARR.

日本語の概要は準備中です。原文の説明を表示しています。

Decide when to order coronary artery calcium (CAC) scoring in a primary-prevention patient and interpret the result per the 2026 ACC/AHA multisociety dyslipidaemia guideline. Covers the Class 1 indication (men ≥40 / women ≥45, borderline / intermediate PREVENT-ASCVD risk, uncertainty about LLT), CAC score interpretation (0, 1–99, 100–299, ≥300, ≥1000), how CAC modifies LDL and non-HDL goals, when to repeat CAC, and pitfalls (incidental CAC on non-cardiac CT, radiation, cost). Use when a clinician asks should I order a CAC score, CAC indications, what does CAC 150 mean, treatment goals with CAC score, repeat CAC frequency, CAC in a smoker, CAC vs CCTA, is CAC useful in intermediate risk. Grounded in the 2026 ACC/AHA multisociety dyslipidaemia guideline.

日本語の概要は準備中です。原文の説明を表示しています。

Set absolute LDL-C, non-HDL-C, and ApoB treatment goals, PLUS percent LDL-C reduction, for a primary-prevention patient on lipid-lowering therapy per the re-introduced treatment goals in the 2026 ACC/AHA multisociety dyslipidaemia guideline. Covers goals by PREVENT-ASCVD category (low / borderline / intermediate / high), by CAC score, in severe hypercholesterolaemia / FH, in diabetes with multiple ASCVD risk factors, and the ApoB targets once LDL-C and non-HDL-C goals are met. Use when a clinician asks what LDL goal to aim for, LDL target for intermediate risk, non-HDL goal, ApoB target, dual goals on statin, patient at goal or not, how low should LDL go, statin not enough what next. Grounded in the 2026 ACC/AHA multisociety dyslipidaemia guideline.

日本語の概要は準備中です。原文の説明を表示しています。

Bedside prescribing reference for Bemdec (bempedoic acid / NEXLETOL) — indication check, dose, statin co-prescribing safety caps, monitoring plan, warnings for hyperuricemia and tendon rupture, and special population guidance. Use when a clinician asks "can I start bempedoic acid", "Bemdec indication", "is bempedoic acid safe with my statin", "patient on Nexletol has joint pain or high uric acid", "bempedoic acid in CKD or liver disease or pregnancy", or any prescribing or monitoring question about bempedoic acid.

日本語の概要は準備中です。原文の説明を表示しています。

Guide a non-stigmatising pediatric obesity consultation using the 5As framework (Ask, Assess, Advise, Agree, Assist) and 4Ms assessment (Metabolic, Mechanical, Mental Health, Social Milieu), based on the CMAJ 2025 guideline. Trigger when a clinician asks how to approach a weight conversation with a child or family, how to use the 5As for obesity, how to assess a child with obesity, or how to conduct a non-judgmental obesity visit.

日本語の概要は準備中です。原文の説明を表示しています。

Calculate and interpret the PREVENT-ASCVD risk score (10-year and 30-year) for primary prevention of atherosclerotic cardiovascular disease per the 2026 ACC/AHA multisociety dyslipidaemia guideline. Covers inputs required, risk-category thresholds (low <3%, borderline 3–<5%, intermediate 5–<10%, high ≥10%), when to use the 30-year calculation (adults 30–59), and how PREVENT differs from the older Pooled Cohort Equations (lower risk estimates by 40–50%, race-agnostic). Use when a clinician asks what the 10-year ASCVD risk is, how to calculate PREVENT, PCE vs PREVENT, risk category for this patient, does my patient need a statin, 30-year risk calculation, primary prevention risk assessment. Grounded in the 2026 ACC/AHA multisociety dyslipidaemia guideline.

日本語の概要は準備中です。原文の説明を表示しています。

Work a primary-prevention patient through the 2026 ACC/AHA multisociety dyslipidaemia guideline CPR framework — Calculate (10-year and 30-year PREVENT-ASCVD), Classify (low / borderline / intermediate / high), Personalize (demographic, clinical, biomarker, and reproductive risk enhancers), and Reclassify (coronary artery calcium scoring where appropriate). Use when a clinician asks how to assess ASCVD risk for primary prevention, who needs a statin, borderline risk patient what to do, intermediate risk should I start a statin, risk enhancers to look for, premature family history of ASCVD how does it change risk, pregnancy-related risk factors, PCOS and cardiovascular risk. Grounded in the 2026 ACC/AHA multisociety dyslipidaemia guideline.

日本語の概要は準備中です。原文の説明を表示しています。

Order and interpret lipoprotein(a) [Lp(a)] measurement at least once in a lifetime, apply the risk-enhancer threshold (≥125 nmol/L or ≥50 mg/dL), and run cascade screening of first-degree relatives for premature ASCVD, familial hypercholesterolaemia, or elevated Lp(a) per the 2026 ACC/AHA multisociety dyslipidaemia guideline. Covers the Class 1 lifetime measurement, how elevated Lp(a) affects LLT initiation and intensification, the cascade screening indications, the interaction of Lp(a) with ASCVD risk estimation, and current therapeutic limitations. Use when a clinician asks when to check Lp(a), how often to repeat Lp(a), elevated Lp(a) what next, treatment for high Lp(a), should I screen my patient's family, Lp(a) and statins, cascade screening indications. Grounded in the 2026 ACC/AHA multisociety dyslipidaemia guideline.

日本語の概要は準備中です。原文の説明を表示しています。

Select the right pharmacologic agent for a child aged 12+ with obesity using the CMAJ 2025 guideline — choosing between GLP-1 receptor agonists, metformin, or orlistat with monitoring guidance. Trigger when a clinician asks which medication to use for pediatric obesity, whether to start semaglutide or metformin in a child, or how to manage obesity pharmacologically in adolescents.

日本語の概要は準備中です。原文の説明を表示しています。

An infographic skill for AI agents — works inside Claude Code, Codex, Hermes, OpenClaw, Cursor, and any agent host that loads skills. Create professional infographics as self-contained HTML files with PNG exports. Use when the user asks to create, design, generate, build, or make an infographic, data visualization, visual explainer, chart poster, cheatsheet, or pocket guide. Trigger phrases include "make this visual", "turn this into a graphic", "visualize this data", "infographic for X", "cheatsheet for X", or when the user provides structured data (tokenomics allocations, ecosystem/partner lists, timelines, comparisons, step-by-step processes) AND asks for a visual output. Covers tokenomics, ecosystem overviews, game overviews, cheatsheets, airdrop guides, comparisons, and process flows. Do NOT trigger for plain text answers, markdown tables, bulleted summaries, questions asking for advice or explanations about a topic (even when the topic is tokenomics, ecosystem, vesting, etc.), inline chat diagrams, or data processing with no visual output requested. The signal is "asks for a visual", not "mentions a keyword".

日本語の概要は準備中です。原文の説明を表示しています。